Rocket Pharmaceuticals, Inc. Amortization of Debt Issuance Costs
Rocket Pharmaceuticals, Inc. (RCKT) reported Amortization of Debt Issuance Costs of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2017-03-16
- Rocket Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2015-12-31 was $0.00, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2015-09-30 was $15.00K, a 74.58% decline year-over-year.
- Rocket Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2015-06-30 was $44.00K, a 20.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. amortization of debt issuance costs for the quarter ending 2015-03-31 was $44.00K, a 13.73% decline year-over-year.
- Rocket Pharmaceuticals, Inc. amortization of debt issuance costs for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- Rocket Pharmaceuticals, Inc. amortization of debt issuance costs for fiscal 2015 was $107.00K, a 51.14% decline from fiscal 2014.
- Rocket Pharmaceuticals, Inc. amortization of debt issuance costs for fiscal 2014 was $219.00K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-16 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $15.00K derived: sum of 2 quarters · filed 2017-03-16 | $59.00K derived: sum of 3 quarters · filed 2017-03-16 | $107.00K 10-K · filed 2017-03-16 |
| 2015-09-30 | $15.00K 10-Q · filed 2016-11-09 | $59.00K derived: sum of 2 quarters · filed 2016-11-09 | $107.00K 10-Q · filed 2016-11-09 | $157.00K derived: sum of 4 quarters · filed 2016-11-09 |
| 2015-06-30 | $44.00K 10-Q · filed 2016-08-10 | $92.00K 10-Q · filed 2016-08-10 | $142.00K derived: sum of 3 quarters · filed 2016-08-10 | $201.00K derived: sum of 4 quarters · filed 2016-08-10 |
| 2015-03-31 | $44.00K 10-Q · filed 2016-05-11 | $98.00K derived: sum of 2 quarters · filed 2016-05-11 | $157.00K derived: sum of 3 quarters · filed 2016-05-11 | $212.00K derived: sum of 4 quarters · filed 2016-05-11 |
| 2014-12-31 | $54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $113.00K derived: sum of 2 quarters · filed 2016-03-23 | $168.00K derived: sum of 3 quarters · filed 2016-03-23 | $219.00K 10-K · filed 2016-03-23 |
| 2014-09-30 | $59.00K 10-Q · filed 2015-11-12 | $114.00K derived: sum of 2 quarters · filed 2015-11-12 | $165.00K 10-Q · filed 2015-11-12 | |
| 2014-06-30 | $55.00K 10-Q · filed 2015-08-07 | $106.00K 10-Q · filed 2015-08-07 | ||
| 2014-03-31 | $51.00K 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |